Purpose miRNAs have been linked to chemosensitivity of breast cancer cells in vitro. In patients, however, there is no clinically validated method for predicting chemotherapy response. The aim of this study was to assess whether (I) a specific pattern of miRNA expression in pretherapeutic biopsies can predict response to neoadjuvant chemotherapy, and (II) differential miRNA expression in residual tumor after completion of chemotherapy allows further prognostic stratification of non-responding patients. Methods Sixty-four patients with newly diagnosed large (C3 cm) or locally advanced primary breast cancers who underwent neoadjuvant anthracycline/taxane-based chemotherapy were included. Relative expression of 10 miRNAs likely to be associated with chemotherapy response (miR-7,-21,-29a,-29b,-34a,-125b,-155,-200c,-340,-451) was determined by quantitative RT-PCR from pretherapeutic biopsies (n = 64) and residual invasive tumor after chemotherapy (n = 42). Pathologic complete response (pCR) defined by absence of invasive tumor served as reference standard. In addition, miRNA expression was compared with disease-free and overall survival. Results Nine (14%) of 64 patients achieved pCR. High expression of miR-7 and low expression of miR-340 in pretherapeutic biopsies predicted pCR with a negative predictive value of 96 and 97%, respectively (specificity 54 and 57%). The combined profile of miR-7 high /miR-340 low demonstrated improved specificity of 86% while maintaining a high negative predictive value (96%) to identify non-responders. Pretherapeutic expression of miR-200c and miR-155 showed prognostic information, and low expression was associated with increased overall survival (115 vs. 90 months, p B 0.03). After chemotherapy, the overall survival of patients with residual invasive tumor was better for those demonstrating low miR-7 or high miR125b (p = 0.01).
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Conclusions Intratumoral expression of miR-7 and miR-340 prior to neoadjuvant chemotherapy could be used to predict pCR and a profile of miR-7 low or miR-340 high identified patients unlikely to achieve pCR who might benefit from alternative treatment options including earlier surgery. Our study identifies miRNAs as promising predictive biomarkers, which could aid in optimization of breast cancer management and treatment stratification.
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Background MicroRNAs (miRNAs) are involved in the development and progression of malignant tumors, mainly through posttranscriptional modulation of oncogenic and tumor suppressor pathways and provide prognostic information [2, 9, 16, 18, 31, 40, 48] . In breast cancer, differential miRNA expression has been demonstrated across breast cancer subtypes, with both tumor-promoting and tumorsuppressive functions for individual miRNAs [5, 8, 15, 17, 23, 44] . A recent study describing the global miRNA expression architecture in more than 1000 human breast cancers confirmed these roles of individual miRNAs and revealed that miRNAs predominantly act as modulaters and fine-tuners of gene expression in these neoplasms [13] .
Few studies have investigated the effect of chemotherapy on miRNA expression patterns or the predictive value of tissue-based miRNA expression profiles. Neoadjuvant systemic chemotherapy is increasingly used in women with newly diagnosed large or locally advanced breast cancer and is considered a valid therapeutic option in patients requiring chemotherapy [25, 47] . Neoadjuvant chemotherapy allows for assessment of treatment response in the resection specimen in addition to potentially reducing tumor volume and enabling more patients to be treated with breast-conserving surgery. Pathologic complete response (pCR) defined by the absence of invasive cancer is an important prognostic parameter associated with improved long-term outcome [11, 36, 43] . While clinical response is observed in up to 70% of patients, only about 15-30% achieve pCR [11, 25, 47] .
Novel predictive biomarkers that can be assessed in the biopsy specimen before chemotherapy could help to individualize treatment decisions and to potentially avoid ineffective chemotherapies. The reliable assessment of miRNA expression profiles is feasible from routine formalin-fixed and paraffin-embedded archival tissues [12, 21, 42] .
In the present study, we explored further the potential of specific miRNAs to serve as predictive markers for response to neoadjuvant treatment in breast cancer. Ten candidate miRNAs were chosen, including four miRNAs (miR-7, -21, -34a and miR-451) previously associated with chemotherapy resistance of human breast cancer cells in vitro [10, 24, 28, 33] , and six miRNAs (miR-29a, -29b, -125b, -155, -200c, and miR-340) that we identified through in silico analysis (described in materials and methods) of published gene expression changes in breast cancers after neoadjuvant chemotherapy [27, 34] .
Materials and methods

Patients
A total of 64 patients with large (C3 cm) or locally advanced (T2 -4) primary invasive breast cancer with or without positive lymph node metastases at the time of presentation were included. All patients had been enrolled in a larger multi-center chemotherapy trial between 1998 and 2002 [41, 46] . Exclusion criteria were known distant metastases and prior chemo-, hormone-, or radiotherapy. Patients received epirubicin and paclitaxel in combination (90 and 175 mg/m 2 ) or sequentially (150 and 250 mg/m 2 ), or epirubicin plus cyclophosphamide (90 and 600 mg/m 2 ) followed by docetaxel (100 mg/m 2 ). After completion of chemotherapy, all patients underwent breast-conserving surgery or mastectomy, followed by three cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil. In addition, patients with positive hormone receptor status received adjuvant tamoxifen for 5 years after completion of chemotherapy, and patients who underwent lumpectomy received radiotherapy of the breast.
For this miRNA analysis, consecutive patients from a single center, University Hospital Klinikum rechts der Isar of the Technische Universität München, were included if tumor tissue from pretherapeutic biopsies was available. Written informed consent for subsequent tissue analysis had been obtained from all patients, and the study protocol for this analysis was approved by the institutional review board.
For all patients, the following histopathological parameters were assessed: invasive ductal versus lobular subtype, grade (according to Bloom-Richardson modified by Elston and Ellis [14] ), estrogen-and progesterone receptor status (positivity defined as [1% positive tumor cells), HER2-status (positivity defined as either IHC-score 3? or amplification by FISH), tumor and nodal stage (ypT, ypN) and histopathologic response following chemotherapy. Last follow-up date was June 2012 and median follow-up time was 112 months. Disease-free and overall survival was calculated from the date of initial diagnosis. The REMARK reporting guidelines have been followed as far as applicable to this study [3] . Patient characteristics are summarized in Table 1 .
Histopathologic response
Pathologic complete response (pCR) was assessed in the surgical specimens post-chemotherapy and defined by the complete absence of residual invasive tumor in the breast, with or without residual non-invasive intraductal carcinoma, and irrespective of lymph node status (ypT0/is, ypNX). All cases with residual invasive tumor of any size were classified as non-responding (non-pCR). Nine (13.6%) patients achieved pCR and 57 (86.4%) patients were histopathologic non-responders.
For assessment of pCR, surgical specimens were cut in 0.5-cm-thick slices and evaluated for the presence of macroscopic tumor. Representative samples were taken from all macroscopically visible putative tumor as well as areas with marked fibrosis or scarring, and microscopically analyzed for the presence of residual tumor. The tumor bed was histologically identified by signs of tumor regression such as fibrosis, inflammation, and presence of macrophages or hemosiderin. Immunohistochemical staining with antibodies against cytokeratins was performed on selected sections to identify or verify tumor residues. The categorization of a case as pCR required extensive sampling from macroscopically suspicious as well as uninvolved areas of the surgical specimens.
Tissue samples
All biopsies and surgical specimens were fixed in 10% formaldehyde for 10-24 h and subsequently paraffin embedded. H&E stained sections of all cases were reviewed by an experienced pathologist (SA) to confirm subtype and grade and assess the percentage of viable invasive tumor cells, fibrosis or necrosis, and percentage of inflammatory cells. Breast cancer samples were further processed if at least one well circumscribed area with a tumor cellularity C70% was present to allow for manual microdissection, and if \10% inflammatory cells or \10% residual lymphocytes in lymph node metastases were present. For all biopsies and surgical specimens, tumor tissue from two or more different locations or biopsy cores was combined to account for intratumoral heterogeneity and avoid sampling bias.
A total of 123 samples from 64 patients showed sufficient tumor cell content, including 64 biopsies before chemotherapy, 42 post-chemotherapy specimens, and 17 lymph node metastases post-chemotherapy.
Selection of miRNA candidates potentially associated with chemotherapy resistance
Four miRNAs, including miR-7, -21, -34a, and miR-451 were previously described to be associated with resistance of human breast cancer cells to anthracycline or taxane chemotherapy in vitro [10, 24, 28, 33 ]. An additional six miRNA candidates were identified through in silico analysis of published gene expression changes in breast cancers after chemotherapy. Perou's seminal study [34] describing ypT tumor stage assessed in the surgical specimen after neoadjuvant chemotherapy, ypN nodal stage assessed in the surgical specimen after neoadjuvant chemotherapy, pCR no residual invasive tumor in the breast, with or without residual non-invasive intraductal carcinoma, and irrespective of lymph node status (ypT0/is, ypNx) intrinsic molecular subtypes of breast cancer had also included gene expression profiles of 20 breast cancers before and after neoadjuvant anthracycline-based chemotherapy. A subsequent reanalysis identified 17 genes that showed significant changes in expression after neoadjuvant chemotherapy [27] . We utilized this set of 17 genes to identify potential regulatory miRNAs by in silico analysis. Three different algorithms were used to predict putative regulatory miRNAs, including TargetScan [30] (Version 6.0), microRNA.org [4] (Release 10/2010) and PicTar [29] . miRNAs predicted to regulate two or more of the 17 genes or miRNAs predicted by 2 or more algorithms were chosen as candidates, including miRNAs miR-29a, -29b, -125b, -155, -200c, and miR-340.
RNA extraction
All tissue samples from the same patient (before and after chemotherapy) were processed simultaneously. Total RNA including small RNAs was extracted using the FFPE miRNeasy Kit (Qiagen, Hilden, Germany). We had previously studied the influence of various extraction parameters on quality and quantity of RNA, and a section thickness of 10 lm and buffer volume of 150 ll were determined as optimal [37] . For each sample, between 2 and 20 unstained 10 lm sections were manually microdissected after deparaffinization, and RNA was extracted using 150 ll proteinase K digestion buffer according to manufacturer's instructions. Total RNA was measured with a NanoDrop photospectrometer (NanoDrop, Wilmingtom, DE).
miRNA expression analysis by quantitative PCR using TaqMan miRNA Assays
The expression of 10 miRNAs, including miR-7, -21, -29a, -29b, -34a, -125b, -155, -200c, -340, and miR-451, as well as small nucleolar RNA U48 for normalization, was determined by quantitative reverse-transcription polymerase chain reaction using TaqMan miRNA Assays (Applied Biosystems, Carlsbad, CA, USA). We had previously determined RNU48 as optimal reference for normalization, showing least intra-and inter-individual variation and high abundance in a range of breast cancer samples, and demonstrated high technical reproducibility of both RNA extraction procedure and quantitative PCR analysis for assessment of miRNA expression [37] . The assays were performed according to the manufacturer's instructions, scaling the total reaction volume to 10 ll each for the reverse transcription and the real-time PCR amplification reaction. A standard input of 6 ng total RNA (manufacturer's recommendation 1-10 ng) was used, and 3 and 9 ng were used as control input to confirm that the RT reaction is performed within a linear dynamic range. Two negative controls were included in the RT, including one reaction without template and one without enzyme. During real-time PCR, all samples and serial dilutions were run in triplicates, and negative controls in duplicates.
For each individual assay, all 123 samples were analyzed at the same time on two 384-well plates, and corresponding pre-and post-therapeutic samples from one patient were analyzed on the same plate to avoid bias. A pool of 90 samples for which abundant quantity was available was used to prepare serial dilutions. For each assay, a standard curve including 6 serial dilutions was used to calculate and correct for amplification efficiency. Real-time PCR was carried out on a Light Cycler 480 instrument (Roche Diagnostics).
Analysis of quantitative PCR data was performed using the Light Cycler Software (Roche LC Software V1.5), and the arithmetic mean of each triplicate measurement was used for further analysis. Relative quantification of miRNA expression was performed using a non-linear algorithm (second derivative maximum, Roche LightCycler Software V1.5) with a standard curve for each individual assay to calculate and correct for amplification efficiency, and using RNU48 as reference for normalization.
Statistical analysis
The miRNA expression analysis was performed blinded to patients' histopathological response status (pCR). The Mann-Whitney test was used to compare relative expression of a given miRNA between groups of patients. The Wilcoxon signed rank test was used to compare miRNA expression before and after chemotherapy. miRNAs showing a significant association with pCR were used to predict response using the median expression value as a cutoff. The v 2 test was used to calculate the likelihood ratio for an association between low versus high miRNA expression (using median as cutoff) or clinicopathologic parameters and histopathologic response. Box plots are utilized to visualize differences in relative miRNA expression, showing the median (line within the box), 25th and 75th percentiles, and whiskers showing 1.5 times the interquartile range. Spearman's rank correlation was used to assess bivariate relationship of quantitative parameters. Kaplan-Meier analysis and log-rank test were applied to compare survival probability between groups of patients. Multivariate analysis using Cox regression model was performed for various combinations of only two parameters, including miRNA expression and clinicopathologic parameters, to account for the limited number of events. Quantitative parameters are expressed as median and range or mean ± one SD. All statistical analyses were performed at a two-sided 5% level of significance using IBM SPSS Statistics (Version 21).
Results miR-7 and miR-340 expression at baseline is different in patients achieving pCR versus non-PCR and predicts treatment response For all 64 patients, tumor tissue from pretherapeutic core needle biopsies was available to assess miRNA expression at baseline prior to the start of chemotherapy. First, we assessed differences in miRNA expression between patients who achieved pCR (n = 9) versus non-responding patients (non-PCR; n = 55). Two miRNAs demonstrated significant differences in expression, with higher expression of miR-7 (mean 1.6 versus 0.9) and lower expression of miR-340 (mean 2.5 versus 5.7) associated with pCR versus non-pCR (p = 0.02; Fig. 1 ). The expression of miR-7 and miR-340 were not statistically correlated with each other. All other miRNAs did not show an association with pCR.
We next assessed the predictive value of miR-7 and miR-340 to identify treatment response versus non-response (pCR vs. non-pCR). Using the median value as cutoff, high expression of miR-7 and low expression of miR-340 in pretherapeutic biopsies each predicted pCR with a high negative predictive value of 96 and 97%, respectively (corresponding specificity 54 and 57%). The combined expression pattern of miR-7 high /miR-340 low predicted pCR with an equally high negative predictive value of 96% and improved specificity of 86% (Table 2) .
Associations between baseline miRNA expression and clinicopathologic parameters
We next assessed associations between miRNA expression and common clinicopathological tumor characteristics to identify potential confounding factors. A higher expression of miR-7 at baseline was associated with invasive ductal versus lobular subtype (mean 1.0 vs. 0.5; p \ 0.01), grade 3 versus grade 2 (1.1 vs. 0.7; p = 0.04), and HER2-positive versus -negative status (1.1 vs. 0.5; p = 0.04). Lower expression of miR-340 was associated with HER2-negativity (mean 4.0 vs. 7.7; p \ 0.01) and estrogen receptor-positive/HER2-negative subtype (mean 4.0 vs. 6.5; p = 0.02). All statistically significant associations between miRNA expression and clinicopathologic parameters are summarized in Table 3 .
Predictive value of clinico-pathologic parameters for pathologic response (pCR)
To further assess potential confounding factors, we assessed possible associations between clinicopathologic parameters and pCR. Patients with invasive ductal carcinoma showed a tendency for better response to chemotherapy compared to lobular carcinomas, although this was not statistically significant. We did not observe statistically significant associations between tumor grade, hormone receptor-or HER2-status and subsequent pCR in this patient cohort.
Expression of miR-200c and miR-155 at baseline provides prognostic information
We next assessed the prognostic value of miRNA expression at baseline prior to the start of neoadjuvant Despite being associated with response, miR-7 and miR-340 demonstrated no association with survival. The pretherapeutic expression levels of other miRNAs were not associated with survival. Amongst clinicopathologic parameters, estrogen receptor positivity, grade 2 (versus 3), and negative nodal status after chemotherapy were significantly associated with longer overall survival, and patients achieving pCR showed a tendency for longer disease-free and overall survival, although this was not statistically significant (Table 4) Similarly, low miR-155 remained significantly associated with longer overall survival in multivariate combinations with tumor grade (p = 0.01) and HER2 status (p = 0.04), and remained borderline significant in combinations with ER status (p = 0.07), negative nodal status after chemotherapy (p = 0.06), and pCR (p = 0.05).
Expression of miR-7 and miR-125 in residual invasive tumor provides prognostic stratification of non-responding patients
Out of 55 non-responding patients (non-pCR), sufficient residual tumor to allow for microdissection and miRNA analysis was obtained from 42 patients. miRNA expression in residual invasive tumor after chemotherapy provided additional prognostic stratification of histopathologic nonresponders. Using the median expression value as cutoff, low expression of miR-7 was associated with longer disease-free (100 vs. 52 months, p = 0.01) and overall survival (119 vs. 83 months; p = 0.03). Similarly, high (Fig. 3) . All other miRNAs showed no association with survival parameters. Overall, the majority of miRNAs (miR-7, -21, -155, -200c, -340) showed a significant decrease in expression in residual tumor after chemotherapy compared to baseline, while two miRNAs, miR-125b, and miR-34a showed a significant increase (Supplementary Table 1) .
Axillary lymph node metastases were obtained from 17 out of 55 non-responding patients after chemotherapy. There was no consistent association between miRNA expression in the primary tumor and corresponding lymph node metastases.
Discussion
We demonstrated that high intratumoral expression of miR-7 and low expression of miR-340 predicted pathologic complete response (pCR) of breast cancer prior to anthracycline/taxane-based neoadjuvant chemotherapy. In the neoadjuvant setting, the early identification of non-responding breast carcinomas (non-pCR) would be most important to avoid ineffective treatments and potentially switch to alternative therapies earlier such as surgery or using a non-cross resistant chemotherapy regimen. High intratumoral expression of miR-7 and low expression of miR-340 prior to neoadjuvant chemotherapy identified histopathologic non-response (non-pCR) with a high negative predictive value (96-97%) identifying more than about half of patients that would have non-pCR at completion of neoadjuvant chemotherapy (specificity 54-57%). Using a combined profile of miR-7 high /miR-340 low identified non-responding patients with an improved specificity of 86% maintaining a high negative predictive value of 96%. A high negative predictive value is desirable to allow possible changes to an alternative non-cross resistant chemotherapy regimen in non-responders, while assuring that therapy is not withheld from potentially responding patients. Of note, the predictive value of miR-7 and miR-340 expression for histopathologic response was independent of previously established clinicopathologic parameters such as tumor grade or tumor subtype.
Little is known so far about the predictive value of tissue-derived miRNAs, but few studies assessed changes in circulating miRNAs from plasma samples during neoadjuvant chemotherapy. However, changes in plasma and tumor-based miRNA were not associated with each other as non-tumoral sources such as endothelial-derived miRNAs may have contributed to the pattern of circulating miRNAs in plasma [7, 20] . Zheng et al. reported increased miR-125b and miR-141 associated with non-pCR after anthracycline-taxane based chemotherapy in 21 breast cancers [50] . In 246 patients with estrogen receptor-positive breast cancers, higher levels of miR-30 and miR-182 were associated with benefit from adjuvant tamoxifen treatment and longer progression-free survival [38] . miR-7 was chosen in our panel, because this microRNA has been previously associated with chemotherapy resistance [24, 35] and was linked with tumor suppressor properties [49] and immunosurveillance of breast cancer cells in vitro [1] . miR-7 was downregulated in taxane-and platinum resistant MCF-7 breast cancer cells [24, 35] and was suggested to regulate a drug efflux pump (multidrug resistance protein 1) [35] which is often upregulated in residual breast cancer after anthracycline-and/or taxanebased chemotherapy [26, 39] . Furthermore, breast cancer cells with upregulated miR-7 expression have been found to be more susceptible to cytotoxic T lymphocytes and may therefore contribute to a favorable immune response [1] .
miR-340 has not been previously linked with chemoresistance. Using in silico analysis, we identified that miR-340 is predicted to target several genes that were previously reported to be upregulated in breast cancer specimens after anthracycline-based chemotherapy [27] . miR-340 is also predicted to regulate tumor growth and proliferation, including Jun-and Fos-oncogenes, Cyclin Dependent Kinase 5 (Cdk5) and Connective Tissue Growth Factor (CTGF).
In our study, low intratumoral expression of miR-200c and miR-155 at baseline were both significantly associated with longer disease-free and overall survival (115 vs. 90 and 117 vs. 89 months; p B 0.03). The prognostic value of both miRNAs was independent of other clinicopathologic parameters, and low expression of miR-200c and miR-155 in baseline biopsies was better in predicting overall survival than pCR, estrogen receptor and HER2 status or tumor grade. The best prediction of overall survival was achieved by negative nodal status after chemotherapy. While miR-155 has a well-known oncogenic role in solid cancers including breast cancer (reviewed in [22, 32] ) and its downregulation could conceivably be associated with good prognosis, the prognostic value of miR-200c in breast cancer is less well established. A recent study found opposing prognostic effects of miR-200c in progesterone receptor-positive versus -negative breast cancers [45] .
Achievement of histopathologic complete response (pCR) correlates with improved long-term outcome, in particular for aggressive triple-negative or HER2-positive breast cancer subtypes [6, 11, 19, 25, 47] . However, the majority of patients do not achieve pCR. Further prognostic stratification of this large and heterogeneous group of nonresponders would be clinically desirable but reliable markers are currently lacking.
We observed that tumor tissue levels of most miRNAs showed a treatment induced decrease in expression; however, miR-125b and miR-34a were significantly increased after chemotherapy. This is in line with a prior report of increased miR-34a in residual tumor after neoadjuvant chemotherapy [20] .
Our results demonstrate that patients with residual tumor with high expression of miR-125b and low expression of miR-7 showed longer overall survival of 116 versus 77 months (p \ 0.01) and 119 versus 83 months (p = 0.03), respectively. This information might be not translatable to different treatment stratification at this time; nevertheless, patients with a poorer prognosis might benefit from closer surveillance for disease recurrence.
Our study has some limitations related to the retrospective nature and limited size of the patient cohort (n = 64 patients; n = 123 samples). An important strength is the homogenous cohort consisting of consecutive patients from a previously reported clinical trial, which included large and locally advanced, higher grade (G2-3) breast cancers who received the same treatment regimen of epirubicin plus taxane chemotherapy [41, 46] . Furthermore, tumor tissue from two or more individual locations or biopsy cores was combined in each case to account for intratumoral heterogeneity and to avoid sampling bias. All samples were microdissected to ensure high tumor cell content ([70%). Our selection of miRNA candidates was performed prospectively based on mechanistic associations with chemosensitivity/resistance in vitro or based on predicted regulation of target genes that are altered in breast cancer after chemotherapy.
Based on our findings, further prospective studies are necessary to confirm the predictive value of these miRNAs in defined breast cancer subtypes and for different therapeutic regimens such as those containing anti-HER2 treatment in addition to chemotherapy.
Conclusions
In conclusion, our results establish a potential role for using aberrant miRNA expression in predicting response or resistance to chemotherapy as well as disease-free and overall survival in breast cancer. This information could be used for treatment stratification considering alternative treatment options. In addition, miRNA-targeted therapies are under investigation, and our results may provide a rationale for further assessment of miR-7 or miR-340 as targets to enhance chemosensitivity or manage drug-resistant breast cancers in the future. Translational Science Collaborative of Cleveland (KL2TR000440) from the National Center for Advancing Translational Sciences (NCATS) component of the NIH.
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